Long-Term Data Reinforces Combination Therapy’s Efficacy

New data published August 1,2025,in Nature Medicine demonstrates ⁤the lasting benefits of combining pembrolizumab (Keytruda) and axitinib (Inlyta) for patients battling advanced clear cell renal cell carcinoma (ccRCC). The‌ phase‌ 3 KEYNOTE-426 trial (NCT02853331) reveals notable improvements ⁣in overall survival, progression-free survival, and objective response rates compared to sunitinib (Sutent) alone.

Survival Rates Demonstrate a Clear Advantage

The study followed patients with newly diagnosed stage IV or recurrent ccRCC who had not previously received treatment.​ patients were randomly assigned to receive either the pembrolizumab and axitinib combination ⁤or sunitinib. The analysis, conducted after a longer follow-up period, showed ⁤a median ‍overall survival of​ 47.2⁢ months for those receiving the combination therapy, ​compared to‍ 40.8 months for those on sunitinib alone (HR, 0.84; 95% CI, 0.71-0.99).

Looking at longer-term outcomes, the​ rates ‍of survival at 36, 48, and 60 months were notably higher in the combination arm: 62.6% vs 53.8%,‍ 49.2% vs 45.0%,⁣ and 41.9% vs 37.1%, respectively. This sustained benefit suggests a durable impact of the immunotherapy-based regimen.

Subgroup Analysis Highlights Broad Applicability

importantly, the benefits of the pembrolizumab and axitinib combination weren’t limited to ‌the overall patient population. ‍ Subgroup analyses revealed significant advantages for specific groups, including:

• patients younger than 65 years (HR, 0.74; 95%⁢ CI,⁣ 0.59-0.92)
• Female patients (HR, 0.63; 95% CI, 0.46-0.88)
• Patients with a poor IMDC risk category (HR, 0.51; 95% CI, 0.33-0.80)

These findings suggest the combination may be particularly ‍effective ⁢for patients traditionally considered to have a poorer prognosis.

Progression-Free Survival‍ and Response Rates⁤ Also Improved

Beyond overall survival, the combination therapy ⁣also‍ demonstrated ⁢improvements in ⁤progression-free survival (PFS). the median PFS was 15.7 months with pembrolizumab and ⁤axitinib, compared to 11.1 months with sunitinib (HR, ‌0.69; 95% CI, 0.59-0.81).At 36, 48, and 60 months, PFS rates were 29.2% vs 16.0%, 20.9% vs 11.9%, and 18.3% vs​ 7.3%, respectively.

The confirmed objective response rate (ORR) was also substantially higher​ in the combination arm (60.6%) compared to the ‍sunitinib ​arm (39.6%). Moreover, the median duration of response was longer with the combination – 23.6 months versus 15.3 months.

What ⁣This‍ Means for Patients

These long-term results from the KEYNOTE-426⁢ trial solidify‍ pembrolizumab plus axitinib as a valuable treatment option for patients with advanced ccRCC. The sustained improvements in survival, progression-free survival